These results indicate that treatment of psoriasis patients with biologics such as IL-17 inhibitors and TNF-α inhibitors may restore skin barrier dysfunction, preventing suppression of IL-37 expression in psoriasis. This evidence concerns the gene TNF and psoriasis.